1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19234
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsanadis, G.en
dc.contributor.authorVartholomatos, G.en
dc.contributor.authorKorkontzelos, I.en
dc.contributor.authorAvgoustatos, F.en
dc.contributor.authorKakosimos, G.en
dc.contributor.authorSotiriadis, A.en
dc.contributor.authorTatsioni, A.en
dc.contributor.authorEleftheriou, A.en
dc.contributor.authorLolis, D.en
dc.date.accessioned2015-11-24T18:58:00Z-
dc.date.available2015-11-24T18:58:00Z-
dc.identifier.issn0268-1161-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19234-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAntithrombin III/analysisen
dc.subjectFactor V/geneticsen
dc.subjectFemaleen
dc.subjectGene Frequencyen
dc.subject*Genetic Predisposition to Diseaseen
dc.subjectGenotypeen
dc.subjectHeterozygoteen
dc.subjectHormones/blooden
dc.subjectHumansen
dc.subjectMethylenetetrahydrofolate Reductase (NADPH2)en
dc.subjectOdds Ratioen
dc.subjectOxidoreductases Acting on CH-NH Group Donors/geneticsen
dc.subjectPolycystic Ovary Syndrome/*blood/*geneticsen
dc.subjectProtein C/analysisen
dc.subjectProtein S/analysisen
dc.subjectProthrombin/geneticsen
dc.subjectThrombophilia/*geneticsen
dc.titlePolycystic ovarian syndrome and thrombophiliaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11821270-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2002-
heal.abstractBACKGROUND: Polycystic ovarian syndrome (PCOS) is associated with insulin-induced plasminogen activator inhibitor-1 (PAI-1) elevations. Since thrombophilic states correlate with high miscariage rates, as does PCOS, this study aimed at looking for thrombophilic predisposition in PCOS women compared with non-PCOS controls. METHODS: The prevalence of antithrombin III, protein S and protein C deficiencies, as well as factor V Leiden, prothrombin G20210A factor and methylene tetrahydrofolate reductase (MTHFR) mutations, was compared between two different groups of women, one with PCOS (n = 30) and one without PCOS (n = 45). RESULTS: Median proportions of activated protein C, S and antithrombin III as well as the activated protein C ratios were within normal ranges in both samples. There was no evidence that the genetic analysis for factor V Leiden or prothrombin factor differed between the two samples. The odds ratio (OR) of bearing a mutation on the MTHFR gene was 1.2-fold higher [95% confidence interval (CI) 0.470-3.065] in women with PCOS than in women without (P = 0.83). Although this difference is not statistically significant, it might indicate a slightly higher prevalence of heterozygous genotypes in women with PCOS (OR = 1.197, 95% CI 0.473-3.034). CONCLUSIONS: Molecular risk factors of hereditary thrombophilia do not show increased prevalence in women with PCOS in comparison with women in the general population. The existence of a possible trend towards higher prevalence of MTHFR mutation in women with PCOS needs further study, particularly regarding homocysteine levels.en
heal.journalNameHum Reproden
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Tatsioni-2002-polycystic ovarian syndrome.pdf75.93 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons